Treatment of antibiotic thyroid in women, but the normal thyroid function with a medicine called Levothyroxina, does not allow the delivery of a baby of life, suggests new research by the University of Birmingham.
The research carried out by researchers from the Institute for Metabolism and System Research at the Clinical Trials Unit of Birmingham, published today (March 23). New England Journal of Medicine. Financed by MRC and the National Institute for Health Research (NIHR), the research was presented at ENDO 2019, the annual meeting of the American Endocrine Society.
The miscarriage that occurs when one understands five women is one of the most common pregnancy complications. Previous studies have found a strong link between thyroid peroxidase and the presence of antibodies to abortion. However, there has been no clear and previous evidence that the treatment with normal thyroid function and the thyroid peroxidase antibody improves direct birth rates with Levothyroxin.
The University of Birmingham currently manages the largest study of this type of Levothyroxine, which increases the life rates of treatment that occurs in pregnancy over the last 34 decades or with thyroid antibodies during pregnancy, as well as the history of motherhood or wealth.
Dr. Rima Dhillon-Smith, a senior academic professor at the University of Birmingham, said: "Our research found Levothyroxin treatment before pregnancy, normal thyroid function and thyroid peroxidase due to women with antibodies like antibodies. Infertility does not improve the chances of birth. .
"We were surprised that the results of our research had suggested that previous studies suggest that it could benefit from thyroid anti-thyroid treatment."
According to the official thyroid function, a total of 940 women from the UK's 49 hospitals were investigated, with thyroid peroxidases being positive antibodies. They had history decorated or infertility, trying to understand them with a natural or assisted conception.
Studies conducted between 2011 and 2017 470 women received daily 50mcg Levothyroxine and 470 women every day received a placebo. Participants took medication and started up and continued until the end of pregnancy.
The results of both groups were similar: Levasthroxine received 470 (56.6%), 266 women and placebo received 470 (58.3%), 470 (58.3%), 266 women were pregnant; 176 women (37.4%) took Levothyroxina and 178 (37.9%) had a placebo when they had a birth.
Dr. Rima Dhillon-Smith added: "Thyroid peroxidase has been found in the bloodstream with about 10 women with normal thyroid function, which are associated with a higher risk of depression and a higher risk of birth.
"International standards are now recommended for thyroid treatment with a similar Levothyroxine antibody, because it is not intended to help increase the chance of harm and minimal damage.
"Our research is high and high quality, probably Levothyroxine does not improve the success of pregnancy as a result of thyroid antibodies and normal thyroid function, so they would not be recommended or used in clinical practice. Unnecessary medication for women who are not needed."
Dr. Kristien Boelaert, at the University of Birmingham, also said: "Our trial has responded to a definitive and important clinical question.
"In a recent survey based on the clinical fertility of the UK, nearly 40% said that they used the Levothyroxine with a thyroid peroxidase antibody that was commonly used.
"Now, we question whether the thyroid peroxidase-antibody tests should be performed by women with infertility or previous abortions.
"Thyroid peroxidase is also tested for antibodies, but it may provide information on the future progression of thyroid disease, our study has shown that its treatment does not improve Levothyroxin's results and causes anxiety and unnecessary health costs.
"We expect that national and international standards have been updated to eliminate the current recommendations that make use of Levothyroxina in these women.
"We also hope that thyroid peroxidase will take into account the current practice of antibodies similar to high-risk antibodies in high-risk populations."